| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| HLA-A*0301 & B2M & KRASG12V (VVGAVGVGK) | Biotinylated Human HLA-A*03:01&B2M&KRASG12V (VVGAVGVGK) Complex Protein (Monomer, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |   | |||
| HLA-A*0301 & B2M & KRASG12V (VVGAVGVGK) | PE-Labeled Human HLA-A*03:01&B2M&KRASG12V (VVGAVGVGK) Tetramer Protein | Human | HEK293 | $410.00 25ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| DNDI-6148 | DNDI-6148 | Phase 1 Clinical | Drugs For Neglected Diseases Initiative | Infections; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral | Details |
| AN-3661 | AN-6426; AN-3661 | Phase 1 Clinical | Anacor Pharmaceuticals Inc | Malaria | Details |
